open access

Vol 18, No 2 (2015)
Case Report
Published online: 2015-07-31
Submitted: 2015-07-31
Accepted: 2015-07-31
Get Citation

124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma

Angelina Cistaro, Natale Quartuccio, Federico Caobelli, Arnoldo Piccardo, Rosario Paratore, Pietro Coppolino, Alessandro Sperandeo, Gaspare Arnone, Umberto Ficola
DOI: 10.5603/NMR.2015.0024
·
Pubmed: 26315872
·
Nucl. Med. Rev 2015;18(2):102-106.

open access

Vol 18, No 2 (2015)
Case Report
Published online: 2015-07-31
Submitted: 2015-07-31
Accepted: 2015-07-31

Abstract

Neuroblastoma is the most common extra-cranial solid tumor in pediatric patients. Despite the established role of 123I-MIBG and 131I-MIBG scintigraphy in this tumor, only limited data are available regarding the use of 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT). We present our preliminary experience with 124I-MIBG PET/CT: two pediatric patients affected by neuroblastoma, who underwent 124I-MIBG PET/CT for pre-therapy distribution evaluation and restaging purposes. We aimed to evaluate whether 124I-MIBG PET/CT can detect as many or more neuroblastoma lesions than 123I/131I-MIBG imaging. Our cases show promising results, although further validation and standardization of 124I-MIBG PET/CT are required.

Abstract

Neuroblastoma is the most common extra-cranial solid tumor in pediatric patients. Despite the established role of 123I-MIBG and 131I-MIBG scintigraphy in this tumor, only limited data are available regarding the use of 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT). We present our preliminary experience with 124I-MIBG PET/CT: two pediatric patients affected by neuroblastoma, who underwent 124I-MIBG PET/CT for pre-therapy distribution evaluation and restaging purposes. We aimed to evaluate whether 124I-MIBG PET/CT can detect as many or more neuroblastoma lesions than 123I/131I-MIBG imaging. Our cases show promising results, although further validation and standardization of 124I-MIBG PET/CT are required.

Get Citation

Keywords

neuroblastoma, 124I-MIBG PET/CT, bone metastases, 123I-MIBG scan, radiometabolic therapy

About this article
Title

124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma

Journal

Nuclear Medicine Review

Issue

Vol 18, No 2 (2015)

Pages

102-106

Published online

2015-07-31

DOI

10.5603/NMR.2015.0024

Pubmed

26315872

Bibliographic record

Nucl. Med. Rev 2015;18(2):102-106.

Keywords

neuroblastoma
124I-MIBG PET/CT
bone metastases
123I-MIBG scan
radiometabolic therapy

Authors

Angelina Cistaro
Natale Quartuccio
Federico Caobelli
Arnoldo Piccardo
Rosario Paratore
Pietro Coppolino
Alessandro Sperandeo
Gaspare Arnone
Umberto Ficola

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl